News topic
Research News & Updates
New study readouts, preclinical results, and mechanism-of-action research relevant to peptide therapy.
12 articles in this topic
Stanford Discovers "Natural Ozempic" Peptide That Cuts Appetite 50% Without GI Side Effects
Stanford researchers used an AI tool called Peptide Predictor to scan all 20,000 human protein-coding genes and discovered BRP — a naturally occurring 12-amino-acid peptide that reduced food intake by 50% in mice and minipigs without the GI side effects of semaglutide. The study was published in Nature.
New Study: Tirzepatide Causes More Muscle Loss Than Semaglutide in 8,000-Patient Analysis
A real-world analysis of 8,000 patients published in April 2026 found that tirzepatide caused significantly more lean body mass loss than semaglutide at every time point measured — raising new questions about the muscle cost of greater weight loss.
Semaglutide Fails Alzheimer's Trial: What the EVOKE Results Mean for GLP-1 Brain Claims
The largest clinical trial of semaglutide for Alzheimer's disease — the EVOKE program, enrolling 3,808 patients across 566 sites in 40 countries — failed to slow cognitive decline. But the biomarker data tells a more nuanced story, and the Parkinson's evidence remains stronger.
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
The SURMOUNT-5 trial settled the debate: tirzepatide produces 47% more weight loss than semaglutide. But the full picture is more nuanced than the headline.
GLP-1 Drugs and Cancer Risk: What the Research Actually Shows
The thyroid cancer boxed warning. The cancer-protective speculation. A 50-trial meta-analysis. Here is what the evidence actually says about GLP-1 medications and cancer risk.
BPC-157 Human Clinical Data: Where We Stand in 2026
With the FDA reclassification restoring compounding access, BPC-157 is back in focus. Here is an honest assessment of where the human evidence stands.
GLP-1 Drugs and Reduced Alcohol Consumption: An Unexpected Effect
Patients on Ozempic and Wegovy increasingly report reduced desire to drink alcohol. The neuroscience behind this effect is becoming clearer — and clinical trials are underway.
What Happens When You Stop Taking Ozempic or Mounjaro? New 2026 Research
A major Cleveland Clinic study of nearly 8,000 patients found that stopping GLP-1 drugs does not lead to the dramatic weight regain many fear. Average regain was just 0.5% at one year. Here is what the research actually shows.
Survodutide: The Dual GLP-1/Glucagon Agonist Targeting Liver Disease and Obesity
Survodutide combines GLP-1 and glucagon receptor agonism to target both obesity and metabolic liver disease — a differentiated approach that could reshape MASH treatment.
Why GLP-1 Drugs Don't Work for 10% of People: Stanford Identifies the PAM Gene Variant Behind GLP-1 Resistance
A Stanford Medicine study published in Genome Medicine found that roughly 10% of people carry genetic variants in the PAM enzyme that reduce their response to GLP-1 drugs like semaglutide and tirzepatide — a finding that could reshape how doctors prescribe weight loss and diabetes medications.
MariTide: Amgen's Monthly Weight Loss Injection That Could Replace Weekly GLP-1 Shots
Amgen's MariTide (maridebart cafraglutide) is an antibody-peptide conjugate that could deliver ~20% weight loss with just one injection per month — potentially disrupting the weekly GLP-1 injection market dominated by Ozempic and Zepbound.
CagriSema Phase 3 Results: 20% Weight Loss in REDEFINE Trials, Novo Nordisk Files for FDA Approval
Novo Nordisk's CagriSema — the combination of semaglutide and cagrilintide (an amylin analog) — achieved 20.4% weight loss in the Phase 3 REDEFINE 1 trial, with 60% of participants losing at least 20% of body weight. The company filed for FDA approval in December 2025.